QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains
Paracetamol………………………………… 500 mg
Codeine phosphate …………………………. 8 mg
Cellulose – microcrystalline, Gelatin, Magnesium stearate, Starch – Wheat, Talc – purified
Paracetamol has analgesic and antipyretic activity similar to aspirin. The analgesic effect of paracetamol is thought to be due to inhibition of prostaglandin synthesis in the central nervous system and in the periphery, and, to a lesser extent, by blocking pain impulse generation in the periphery. The antipyretic effect is due to a central action on the hypothalamic heat-regulating centre to produce peripheral vasodilatation and subsequent heat loss.
Codeine phosphate is an opioid analgesic that binds with stereospecific receptors at many sites within the CNS to alter processes affecting both the perceptions of pain and the emotional response to pain. There are multiple sub-types of opioid receptors, each mediating various therapeutic and/or side effects of drugs. Its analgesic effect is thought to be due to its partial metabolic conversion to morphine. Codeine has about one-sixth the analgesic activity of morphine. Codeine can also cause other effects eg CNS depression, nausea and vomiting, orthostatic hypotension and constipation.
It has been shown that the analgesic effects of paracetamol and codeine are additive due to their different mechanisms of action.
Paracetamol is readily absorbed from the gastrointestinal tract with peak plasma concentrations occurring some 30 minutes to 2 hours after ingestion. The onset of therapeutic action is 30 minutes and the duration of effect is 4 hours.
Codeine is well absorbed from the gastrointestinal tract and peak plasma concentrations are reached one hour after oral administration. Onset of action occurs in 15-30 minutes and analgesia is maintained for 4-6 hours.
Paracetamol is rapidly and uniformly distributed into most body tissues. It crosses the placenta and is present in breast milk.
Codeine is rapidly distributed to skeletal muscle, kidneys, liver, gastrointestinal tract, lungs, spleen and brain. It crosses the placenta and is distributed in low levels in breast milk.
Approximately 90-95% of the paracetamol dose is metabolised in the liver, primarily by conjugation with glucuronic acid, sulphuric acid and cysteine. An intermediate metabolite which may accumulate in overdosage is hepatotoxic and possibly nephrotoxic.
Codeine is metabolised mainly in the liver. The major metabolic pathway involves glucuronidation of codeine to codeine-6-glucuronide. Codeine can also undergo O- and N-demethylation catalysed by CYP2D6 and CYP3A4 respectively. Patients who metabolise drugs poorly via CYP2D6 are likely to obtain reduced benefit from codeine due to reduced formation of the active metabolite. About 10% of an administered dose of codeine is converted by O-demethylation to morphine which subsequently undergoes glucuronidation to morphine-3 or morphine-6 glucuronide, or N-demethylation to normorphine.
Approximately 85% of a dose of paracetamol is recovered from the urine within 24 hours after ingestion. About 5% is unchanged, the balance consisting mainly of the glucuronide and sulfate conjugates. The elimination half-life varies from 1 to 4 hours and may be prolonged in acute overdosage, in liver disease, the elderly and the neonate.
Codeine is excreted mainly by the kidneys as its metabolite codeine-6-glucuronide. 5-25% is excreted unchanged and approximately 10% is excreted as unchanged or conjugated morphine. The plasma half-life of codeine is 2-4 hours. Only traces of codeine and its metabolites are found in the faeces.
For the temporary relief of pain and discomfort associated with migraine, earache, period pain and rheumatic pain. Reduces fever.
POSOLOGY AND METHOD OF ADMINISTRATION
Adults and children over 12 years:
One to two tablets to be taken every three to four hours as necessary. The maximum dosage of tablets in 24 hours is 8 tablets.
Children 7 – 12 years:
Half to one tablet to be taken every three to four hours as necessary. The maximum dosage of tablets in 24 hours is 4 doses.
Codalgin should not be given to children under 7 years of age.
- Paracetamol should not be used in patients with active alcoholism as chronic excessive alcohol ingestion predisposes patients to paracetamol hepatotoxicity.
- Paracetamol should not be used in patients with a history of intolerance to the drug.
- Codeine should not be used in cases of acute respiratory depression (eg acute asthma, acute exacerbations of chronic obstructive pulmonary disease) since codeine may exacerbate the condition.
- Codalgin should not be used in patients with a past history of allergic reactions to codeine.
- Hypersensitivity to any of the tablet excipients.
- Due to codeine’s structural similarity to morphine and oxycodone, patients experiencing systemic allergy (generalised rash, shortness of breath) to these drugs should not receive codeine.
- Codeine is contraindicated in patients with diarrhoea caused by poisoning, until the toxic substance has been eliminated from the gastrointestinal tract, or diarrhoea associated with pseudomembranous colitis caused by antibiotic administration since codeine may slow the elimination of the toxic material or antibiotic.
SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
Codalgin should be given with care to patients with impaired renal or hepatic function, viral hepatitis, and to patients taking other drugs which affect the liver. In view of the increased risk of hepatotoxicity, the benefit should be weighed against the risk when administering Codalgin to patients with viral hepatitis or pre existing hepatic disease. In such patients, hepatic function determinations may be required at periodic intervals during high dose or long-term therapy.
Codeine should be used with caution in patients with a history of drug abuse or with recent gastrointestinal tract surgery.
Physical and/or psychological dependence may occur with the repeated administration of codeine. Tolerance may also result following repeated administration.
Codeine should be administered with great caution in patients with head injury, brain tumour or increased intracranial pressure since codeine may increase the risk of respiratory depression and further elevate intracranial pressure. In addition codeine can produce side effects such as confusion, miosis and vomiting which are important signs in following the clinical course of patients with head injuries.
Codeine should be administered with great caution in patients with decreased respiratory reserve (e.g. in emphysema, kyphoscoliosis, hypoxia, hypercapnia or even severe obesity) or cor pulmonale, or chronic obstructive pulmonary disease since codeine may exacerbate respiratory impairment.
Codeine should be administered with great caution if at all in patients with CNS depression, since codeine may exacerbate the condition.
Codeine should be used with caution in elderly or debilitated patients because of the danger of respiratory or cardiac depression.
Codeine should be administered with caution in patients with acute abdominal conditions since codeine may obscure the diagnosis or the course of the disease.
Codeine should be administered with caution in patients with severe inflammatory bowel disease (risk of toxic megacolon may be increased, especially with repeated dosing).
Codeine should be administered with caution in patients with hypothyroidism, adrenocortical insufficiency (eg Addison’s disease), shock, myxedema, acute alcohol intoxication or delerium tremens since codeine may exacerbate the symptoms or increase the risk of respiratory and/or CNS depression.
Codeine should be administered with caution in patients taking Monoamine Oxidase Inhibitors (MAOI’s)
Codeine should be administered with caution in patients with a history of convulsive disorders (convulsions may be induced or exacerbated by codeine).
Codeine should be administered with caution in patients with prostatic hypertrophy, urethral stricture or recent urinary tract surgery since codeine may cause urinary retention.
USE IN CHILDREN:
Codalgin can be given in reduced doses to children 7 years and over.
This medication is not suitable for children under 7 years of age.
USE IN THE ELDERLY:
The elderly are more likely to have age-related renal impairment and may be more susceptible to the respiratory effects of opioid analgesics. Dose reduction may be required.
INTERACTIONS WITH OTHER DRUGS
Salicylates and NSAIDs: Prolonged concurrent use of paracetamol and salicylates or non-steroidal anti-inflammatory drugs may increase the risk of adverse renal effects.
Diflunisal: Diflunisal may increase the plasma concentrations of paracetamol by 50%.
General anaesthetics: Codeine may potentiate the effects of general anaesthetics.
Tranquillisers, sedatives and hypnotics: Codeine may potentiate the effects of these drugs.
CNS depressants: Codeine may potentiate the effects of CNS depressants.
Alcohol: Codeine may potentiate the effects of alcohol and the likelihood of toxicity may be increased by its concomitant use. The likelihood of toxicity may also be increased by the concomitant use of alcohol with paracetamol.
Opioid analgesics: Concurrent use of codeine and other opioid agonists is usually inappropriate as additive CNS depression, respiratory depressant and hypotensive effects may occur. Opioid agonists that decrease gastric emptying will decrease the absorption of paracetamol.
Anticholinergics: Concomitant use of codeine and anticholinergic agents may increase the risk of severe constipation and/or urinary retention. Anticholinergics that decrease the gastric emptying such as propantheline, will decrease the absorption of paracetamol.
Monoamine Oxidase Inhibitors: Non-selective MAOI’s intensify the effects of opioid drugs which can cause anxiety, confusion and significant respiratory depression. Severe and sometimes fatal reactions have occurred in patients concurrently administered MAO inhibitors and pethidine. Codeine should not be given to patients taking non-selective MAOI’s or within 14 days of stopping such treatment. As it is unknown whether there is an interaction between the selective MAOI’s (Reversible Inhibitors of Monoamine Oxidase A) and codeine, caution is advised with this drug combination. The absorption of paracetamol is decreased by MAO inhibitors that decrease gastric emptying.
Barbiturates and antiepileptic medications: The likelihood of toxicity may be increased by the concomitant use of enzyme inducing agents such as alcohol, barbiturates or anti epileptic drugs.
Coumarins: Repeated high doses of paracetamol increase the anti coagulant response to coumarins.
Chloramphenicol: Paracetamol may also increase chloramphenicol concentrations.
Antihypertensives: Hypotensive effects of antihypertensive agents may be potentiated when used concurrently with codeine and lead to orthostatic hypotension.
Antiperistaltic antidiarrhoeals (including kaolin, pectin, loperamide): Concurrent use of these agents with codeine may increase the risk of severe constipation.
Metoclopramide: Drugs that increase gastric emptying such as metoclopramide, may accelerate the absorption of paracetamol. Codeine may antagonise the effects of metoclopramide on gastrointestinal motility.
Neuromuscular blocking agents: Codeine may enhance the effects of neuromuscular blocking agents resulting in increased respiratory depression.
Cholestyramine: Cholestyramine reduces the absorption of paracetamol if given within one hour of paracetamol administration.
USES IN PREGNANCY AND LACTATION
Paracetamol crosses the placenta, however problems in humans have not been documented.
Opioid analgesics cross the placenta. Regular use during pregnancy may cause physical dependence in the foetus, leading to withdrawal symptoms in the neonate. Administration of codeine during labour may cause respiratory depression in the newborn infant.
Use in Lactation:
Paracetamol is excreted in breast milk but neither paracetamol nor its metabolites were detected in the urine of nursing infants after 650 mg maternal dose.
Codeine does pass into breast milk so it should be avoided in breastfeeding women.
Codalgin tablets should not be administered while breast-feeding.
EFFECTS ON ABILITY TO DRIVE AND OPERATE MACHINES
Codalgin may cause drowsiness. Those affected should not drive or operate machinery.
Adverse effects of Codalgin are generally infrequent and include:
Less frequent to rare
Less frequent to rare
Less frequent to rare
Less frequent to rare
Inform doctors with side effects when using medicine.
Overdosage with Codalgin tablets involves treatment of both paracetamol and codeine poisoning.
Symptoms of paracetamol overdosage in the first 24 hours are pallor, nausea, vomiting, anorexia, and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may proceed to encephalopathy, coma and death. Acute renal failure with acute tubular necrosis may develop in the absence of severe liver damage. Cardiac arrhythmias have been reported. Liver damage is likely in adults who have taken 10 g or more of paracetamol, due to excess quantities of a toxic metabolite becoming irreversibly bound to liver tissue.
Symptoms of codeine overdosage include vomiting, hypotension, sweating, central stimulation with exhilaration and convulsions in children, drowsiness, respiratory depression, cyanosis, miosis and coma.
STORAGE: Protect from sunlight and moisture, Store below 30ºC.
HOW SUPPLIED: Box of 10 blisters x 10 tablet.
EXPIRY: 24 months from the manufacturing date.
- Read carefully the leaflet before use.
- For further information, please contact your doctor.
- Keep out of reach of children.
SIGMA PHARMACEUTICALS (AUSTRALIA) PTY LTD
286-302 Frankston-Dandenong Road Dandenong South Vic 3175 Australia.